Publications by authors named "Phoebe Dunbar"
NKG2D ligands (NKG2DLs) are broadly expressed in cancer. To target these, we describe an adaptor chimeric antigen receptor (CAR) termed NKG2D/Dap10-12. Herein, T cells are engineered to co-express NKG2D with a fusion protein that comprises Dap10 joined to a Dap12 endodomain.
View Article and Find Full Text PDFArticle Synopsis
- CAR T cell therapy has been effective for treating blood cancers but struggles with solid tumors due to challenging tumor microenvironments.
- Research indicates that CAR T cells with a 'stem-like' phenotype and greater mitochondrial mass have better treatment outcomes.
- The study highlights that overexpressing the transcription factor FOXO1 in CAR T cells can enhance their fitness and effectiveness against solid tumors by promoting a more beneficial metabolic state.
There is significant clinical interest in targeting adenosine-mediated immunosuppression, with several small molecule inhibitors having been developed for targeting the AR receptor. Understanding of the mechanism by which AR is regulated has been hindered by difficulty in identifying the cell types that express AR due to a lack of robust antibodies for these receptors. To overcome this limitation, here an AR eGFP reporter mouse is developed, enabling the expression of AR during ongoing anti-tumor immune responses to be assessed.
View Article and Find Full Text PDF